[Fundamental and clinical investigation of clindamycin-2-phosphate in otorhinolaryngological field (author's transl)].
Some laboratory examinations were made with clindamycin-2-phosphate (CLDM-2-phos.). The drug was applied clinically to several otorhinolaryngological infections and the good results were obtained as follows. 1) Observing by biophotometer, the growth of Staphbylococcus aureus FDA 209P was inhibited well by the serum (diluted 10-fold) 30 minutes, 1, 2, 4 hours after 300 mg of CLDM-2-PHOS. were injected intramuscularly. 2) Serum concentration was determined by thin-layer method with Sarcina lutea ATCC 9341 as the test organism. The peak of serum level was obtained at 1 hour after a single intramuscular injection of 5 mg/kg or 10 mg/kg dosis of CLDM-2-phosphate. The peak of blood concentration was 5.4 mug/ml, 5.6 mug/ml respectively. 3) CLDM-2-phosphate concentration in tissues was estimated one hour after intramuscular injection of CLDM-2-Phosphate. The concentrations in blood and palatine tonsilla were 5.0 mug/ml and 2.9 mug/ml respectively after the intramuscular injection of 10 mg/kg. The concentrations in blood and mucous membrane of maxillar sinusitis were 4.1 mug/ml and 2.5 mug/ml respectively after the intramuscular injection of 10 mg/kg. 4) CLDM-2-phosphate was administered by intramuscular injection into 30 cases with various infections in otorhinolaryngological field. The clinical results were excellent in 22 cases (73.3%), effective in 3 cases (10.0%) and ineffective in 5 cases (16.7%). The effectiveness was 83.3%. 5) No side effects were observed in 30 cases.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D004825:Epiglottis / Q000187:drug effects; D005260:Female; D006801:Humans; D007223:Infant; D007827:Laryngitis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds; D010033:Otitis Media / Q000188:drug therapy; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D010309:Parotitis / Q000188:drug therapy; D000039:Peritonsillar Abscess / Q000188:drug therapy; D012852:Sinusitis / Q000188:drug therapy; D013492:Suppuration; D014069:Tonsillitis / Q000188:drug therapy
D009943:Organophosphorus Compounds; D002981:Clindamycin